Save the date for our virtual Clinical Vaccinology Update (CVU)!

MVEC are pleased to announce we will be hosting a virtual Clinical Vaccinology Update (CVU) on Thursday 18 and Friday 19 November, 2021.

Program details and ticketing information will be announced shortly via our MVEC Events Page.

The Age: Pfizer and Moderna Covid vaccines now available to all Australians over 60

Health Minister Greg Hunt has announced that from Friday, 1 October Australians aged 60 and over will be able to get Pfizer and Moderna regardless of where they live, expanding vaccine choice for more than 300,000 older people who have been waiting to get vaccinated.

In addition to this, it has also been announced that Victoria will receive an extra 88,900 Moderna doses to assist in state clinics to focus on under 60s, while GP and pharmacies will focus vaccinating those 60 and over.

To read the article in full, please click on the link below:
The Age: Pfizer and Moderna Covid vaccines now available to all Australians over 60

Victorian Government COVID-19 Vaccination Enhancement Grants

The Victorian Government is offering COVID-19 Vaccination Enhancement Grants to pharmacies and general practices interested in maximising their capacity to deliver vaccines across identified geographic areas at higher risk of COVID-19.

The grants are designed to support primary care providers to utilise their full vaccine allocations and to confidently promote access in their local communities as well as fund additional workforce or operational costs associated with maximising COVID-19 vaccine administration.

To find out more information about the grants available, please click on the link below.
Victorian Government COVID-19 Vaccination Enhancement Grants

Moderna pharmacy appointments available via online booking platforms

As community pharmacies begin administering Moderna vaccines across the country, listed below are two available booking platforms that may assist with locating your nearest community pharmacy, and their availability for a vaccine appointment.

MVEC are not affiliated with the sites and the information should be used as a guide only.

You can view the booking platforms via the links below.
Find a Pharmacy


Healthed lecture series featuring Associate Professor Nigel Crawford

MVEC’s Associate Professor Nigel Crawford delivered the COVID-19 Update as part of the recent Healthed Australia online lecture series.

In this lecture, A/Prof Nigel Crawford discussed the following:

  • An update on the latest ATAGI announcements
  • Moderna safety data
  • The booster debate
  • Back to school

To listen to the lecture in full, click on the link below:
Healthed lecture series 28 September: COVID-19 Update

New immunisation reference page: COVID-19 mandatory vaccination directions in Victoria

Due to the potential for high levels of disease transmission and an increased risk of severe disease in vulnerable groups, COVID-19 vaccination has been made mandatory for specific workplaces/industries within Victoria.

Our new reference page outlines the current COVID-19 Mandatory Vaccination Directions Order in place in Victoria, including an overview of the responsibilities for both employers and employees, as well as information regarding the medical exemptions for COVID-19 vaccines.


To read more follow the link below:
MVEC: COVID-19 mandatory vaccination directions in Victoria

ATAGI statement about the need for additional doses of COVID-19 vaccines

The Australian Technical Advisory Group on Immunisation (ATAGI) has released a statement about the need for additional doses of COVID-19 vaccines.

The statement strongly recommends maximising first and second dose vaccine uptake across the community without delay in line with current prioritisation and outbreak response strategies and that two doses of any of the vaccines available in Australia have been shown to protect an individual from COVID-19 and its complications, as well as protecting the community.

ATAGI continues to closely monitor local and international data about the frequency and severity of COVID-19 in fully vaccinated individuals as well as reviewing the international data on the efficacy, effectiveness and safety of additional doses for specific high-risk patient populations, including immunocompromised individuals, and the population more generally. These data will inform future strategies regarding additional vaccine doses.

Additional doses can be defined as:

  • Third doses: Additional COVID-19 doses required as part of the primary course to reach a comparable (optimal) level of protection
  • Booster dose: Additional COVID-19 doses required at a broader population level, to optimise protection due to waning of immunity (loss of protection) over time, with booster doses also leading to improved immune memory.

To read the statement in full, please click the link below:
ATAGI statement about the need for additional doses of COVID-19 vaccines

Webinar recording now available: The Alfred community information session on COVID-19 vaccines

A webinar recording is now available from The Alfred’s community information session on COVID-19 vaccines which was held on Tuesday 21 September.

In this session, Allen Cheng and Associate Professor Nigel Crawford discuss in detail the COVID-19 vaccines, including the safety and efficacy in children over 12 years old, as well as answer questions from the community.

The full recording is available on The Alfred channels or the MVEC Facebook page via the links below:

The Alfred community discussion 21 September
MVEC Facebook page

ABC News: Pfizer to apply for approval for COVID-19 vaccine to be used for five to 11 year-old children

Initial results from the highly anticipated trial involving more than 2,000 children studying the effectiveness and safety of the Pfizer and BioNTech COVID-19 vaccine for children ages 5 to 11 have shown the vaccine is safe and establishes a strong antibody response against the virus.

Despite the initial promising results, it will be some time before an official rollout of vaccines for children ages 5 to 11 both in the US and here in Australia. Once the analysis of the trial is completed, in order to be granted approval, the company is required to provide the FDA with a formal immune “bridging” study which provides data-based evidence that children developed the same antibody levels already proven to be protective in older children and teenagers. The results will be submitted to the Food and Drug Administration (FDA) for review and emergency use authorisation.

To read the article in full, please click on the link below:

Chest Pain Guideline updated in MVEC myocarditis/pericarditis following mRNA vaccines pages

We have updated our COVID-19 FAQs regarding myocarditis/pericarditis following mRNA vaccines page to include the new Chest Pain Guidelines.

PREDICT and ACEM, in consultation with the Australian Technical Advisory Group on Immunisation (ATAGI), the NZ Immunisation Advisory Centre, and the Cardiac Society of Australia and New Zealand (CSANZ) have developed a brief guideline on an approach to the initial assessment and workup of children and adolescents presenting to the ED with vaccine-related symptoms.

To read the guidelines, please refer to the following MVEC pages:
MVEC: COVID-19 FAQs page: myocarditis/pericarditis following mRNA vaccines
MVEC: Myocarditis/pericarditis following mRNA vaccines reference page